| Typicality: | 0.385 |
| Saliency: | 0.317 |
| in february | 4 | temporal |
| for menopausal therapy | 3 | purpose |
| currently | 2 | temporal |
| combination → be approved by → the fda | 14 |
| negative | neutral | positive |
| 0.173 | 0.446 | 0.382 |
| Raw frequency | 14 |
| Normalized frequency | 0.317 |
| Modifier score | 0.500 |
| Perplexity | 42.778 |